Roche Believes Biomarker Could Position Antibody For Severe Asthma For Success
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
During an investor presentation Nov. 7, the Swiss pharma outlined its plans to move lebrikizumab into Phase III next year.